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Carbohydrate antigen 125 (CA-125), traditionally a tumor marker for screening, diagnosis, and monitoring in ovarian
malignancy, had recently been shown increasing evidence and more extensively recognized/explored as a novel
surrogate of heart failure (HF). The exact mechanisms underlying the pathophysiologic link between elevated serum
CA-125 concentration and HF may be multi-factorial, with both mechanical and inflammatory process including
numerous potential cytokines involved. Accumulating data had consistently indicated its diagnostic and prognostic
role in HF patients in various clinical settings, however, there is limited clinical information regarding the
incremental value or head-to-head comparison of such marker to other well-established HF markers. In this brief
review, we aimed to discuss the biosynthesis, and potential insights of underlying pathophysiologies associated
with CA-125 secretion in the scenarios of cardiac structural/functional alterations and HF, and further explored its
current usage and roles in several recent reports.Brief introduction
Carbohydrate antigen 125 (CA-125), also known as
MUC16, is a glycoprotein belonging to the mucin
(MUC) family [1]. Humans CA-125, encoded by
MUC16 gene, contains about 22,000 amino acids and is
heavily glycosylated at the extracellular region (Figure 1),
which can be released from the cell surface by undergoing
proteolytic cleavage and hence released into body fluid, in-
cluding blood, pleural effusion, and ascites. CA-125 was
first detected in ovarian cancer cell line. Subsequent studies
showed that it is normally expressed on the surface of cells
derived from coelomic epithelium, including pleura, epi-
cardium, fallopian tubes, endometrium, and endocervix.
With rich oligosaccharide chains, the physiological role
of CA-125 is considered to protect the epithelial lu-
minal surfaces from physical stress through hydration
or lubrication process [2,3].The role of CA-125 in malignancy and non-cardiac
pathophysiology
Clinically CA-125 has long been used as a marker for
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reproduction in any medium, provided the oraccumulated evidence showed that serum levels of CA-125
is helpful in the monitoring of the cancer and further aid
in risk stratification and prognosis after treatment [7,8].
However, a rise of serum CA-125 level is not limited to
ovarian cancer alone. Other gynaecological malignancies
or non-gynaecological malignancies including lung cancer,
mediastinal teratoma, and even non-Hodgkin’s lymphoma,
have been reported to be associated with a high serum
CA-125 level [9-11]. Apart from malignancies, elevation of
CA-125 can been seen in situations involving several
physiologic or pathologic conditions including early preg-
nancy, menstruation, peritoneal trauma, and ascites of any
cause [12,13]. Hepatic cirrhosis as a cause of CA-125 eleva-
tion, for example, had been mentioned to be the most fre-
quent diagnosis in male patients7. Another example is that
elevation of CA-125 may happen in subjects with pleural
effusion [14]. Based on these findings, clinical interpret-
ation of elevated CA-125 should be exercised with caution,
in part may be due to its restriction in specificity of diag-
nosing a single clinical disease entity or scenario.
The link between CA-125, left-sided cardiac structural/
functional alterations and heart failure
Since CA-125 is expressed in epicardium, it is not sur-
prising that cardiac disorders may be associated with ele-
vated CA-125 levels in the blood. Nagele and associates
firstly reported the findings of clinical or hemodynamicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The Mucin family glycoproteins. (A) There are two classes of mucins generated in the cells: secreted mucins and membrane
associated mucins. (B) Diagram of the structure of CA-125. CA-125 is encoded by the MUC16 gene which is located on human chromosome 19.
CA-125 contains a tandem repeat domain that has repeating sequences high in serine, threonine and proline and is highly O-glycosylated. The
C-terminal domain of CA-125 contains multiple extracellular SEA (sea urchin sperm protein, enterokinase, and agrin) modules, a transmembrane
(TM) domain, and a cytoplasmic tail. CA-125 is also thought to be putatively cleaved at a site in the SEA modules.
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on CA-125, in patients with chronic heart failure before
and after heart transplantation [15]. Duman et al. ever
described a weak association between CA-125 level and
right side pulmonary artery pressure, though in that case
no association was found between CA-125 level and left-
side cardiac hemodynamic (mostly diastolic) parameters
[16]. Similar finding was reported by Kouris et al. [17].
What may merit noteworthy is that, Duman et al. also
showed that CA-125 was associated with left atrial vol-
ume as a supplement to the severity indices of diastolic
dysfunction along with BNP levels [16]. In our recent
work, we demonstrated that in subjects with HF but pre-
served LVEF (HFpEF), CA-125 was actually associated
with LA remodeling in terms of higher volume rather
than other parameters, which may highlight that clinical
significance or findings that diastolic impairment or left
sided hemodynamic disturbances linked to CA-125 may
actually come from left atrial remodeling [18]. On the
contrary, D'Aloia et al. demonstrated an association be-
tween CA-125 level and both right heart hemodynamics
and left ventricular diastolic function [19]. Compared to
the former study, data reported by D'Aloia et al. had larger
total patient population across a wide range of HF severity
in terms of NYHA functional class (Fc) (Duman et al.: 49,
Kouris et al.: 77 versus D'Aloia et al.: 286) leading to
larger amount of Fc IV population (Duman et al.: 16,
Kouris et al.: 16 versus D'Aloia et al.: 83) in D'Aloia's series,
and potentially higher number of subjects (28/49 versus152/286) having CA-125 above normal range (35 U/ml).
Differences in total patient numbers, disease severity and
distributions may in part explain the potential differences
in such correlations. In the same study, D'Aloia also
reported that subsequently lower CA-125 at follow up was
related to clinical improvement by NYHA class as a posi-
tive response to therapy. Again, another study by Vizzardi
et al. with larger patient number enrolled and wider range
of clinical HF subjects (n = 200, NYHA Fc II-IV) reported
that both systolic and diastolic indices, cardiac diameter,
and diastolic functional parameters correlated with CA125
level [20]. In one study, CA-125 distinguished subjects
with acute decompensated HF [21], and further showed
prognostic significance (Table 1). The predictive value
for all-cause mortality up to 6-months after index HF
hospitalization had also been demonstrated by the same
study group [22]. On the other hand, there also seems
to be a moderate correlation between CA-125 and brain
natriuretic peptide (BNP) level, the most commonly used
biomarker reflecting degree of excessive ventricular wall
stress, hemodynamics or ventricular filling abnormalities in
left-sided HF [23,24]. Interestingly, though both markers
had been reported to rise in acute heart failure, combin-
ation of them in clinical use may further improve risk strati-
fication at follow up [23,25]. Nevertheless, the elevation of
CA-125 in the context of left-sided HF had been proposed
to be associated with disease severity in terms of NYHA
functional class, [20,22] echocardiographic parameters, and
clinical conditions such as effusions or edema [13,23].
Table 1 Comparisons of previous CA-125 related heart failure research and reports from previous studies
Subjects number HF presentations Clinical status Left side hemodynamics Outcomes available
Kouris et al. [17] N = 77 AHF V V ?
Nunez et al. [21] N = 1,111 AHF V ? V
Nägele et al. [15] N = 71 CHF V ? V
D’Aloia et al. [19] N = 286 CHF V — V
Vizzardi et al. [20] N = 200 CHF V V ?
Duman et al. [16] N = 49 CHF V V ?
Chen [24] N = 285 CHF V V ?
Yilmaz et al. [28] N = 150 All comers ? V V
Hung et al. [18] N = 35 HFpEF X V V
V, Positive Finding, —, Negative Finding, ?, Not Reported.
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heart failure
Significant elevation of CA125 level in a patient having
atrial septal defect (ASD) with right ventricular dilatation
was ever reported by Mathew et al. [26]. The association
between CA125 and right ventricular parameters, either
structural or functional, in subjects presented as chronic
obstructive pulmonary disease (COPD) had also been
described [27,28]. In Yilmaz’s work, 40 patients with
another age- and gender-matched control group with
detailed transthoracic echocardiography were examined
[28]. They observed that patients with higher systolic
pulmonary artery pressure as well as lower tricuspid annu-
lar plane systolic excursion or worse tricuspid annulus
systolic velocity (S’) all had significantly higher CA-125
levels than did those without. In another retrospective
work (totally 150 patients enrolled) by Yilmaz et all
reported that elevated CA-125 level was associated with
worse left ventricular ejection fraction and positively
correlated with systolic pulmonary artery pressure [29].
In particular, patients with right ventricular dilatation
had significantly higher CA-125 levels compared to those
without. They also concluded that patients with high
CA-125 level encountered more frequent hospitalization,
atrial fibrillation and mortality at future follow up. This
work actually pointed out the potential link between
bi-ventricular failure and elevated CA-125 level was
not confined to only right or left ventricle alone.
Possible mechanisms linking elevated CA-125 to clinical
heart failure
Interpretation of elevated CA-125 levels in HF should
consider the triggering factors as well as the production
sites. These issues have been investigated and no simple
answer was found. So far, production of CA-125 in sub-
jects with HF had been hypothesized to happen with so-
called “stressed” mesothelial cells, in response to both
hemodynamic and inflammation stimuli [30]. It had beenproposed that fluid overload accompanied by high venous
pressure due to heart failure may increase the congestion
and hydrostatic pressure in mesothelium, [31] which may
actually provoke the release of several inflammatory
markers such as interleukin-6 (IL-6), interleukin-10 (IL-10),
and tumor necrosis factors. In this regard, serosal irritation
due to inflammation process, mechanical stress, or fluid
congestion all might stimulate mesothelial cells to initiate
CA-125 synthesis [32,33]. The synthetic capacity of meso-
thelium of CA-125 had been demonstrated by Zeillemaker
et al., who investigated the secretion pattern of CA-125
using mesothelial cell monolayer as an in vitro model [34]
by utilizing several inflammatory cytokines including
interleukin-1 (IL-1), tumor necrosis factor-α and lipopoly-
saccharides as stimuli. Apical secretion of CA-125 was
shown in 6 hours, with the most effective stimuli observed
to be IL-1. Congestion as a hallmark of clinical HF mani-
festation may involve pulmonary congestion/edema, pleural
effusion and ascites, which are believed to be interrelated
with systemic inflammation activation as a vicious cycle
[35]. The formation of congestion itself as a consequence
of HF had made the splanchnic bed with an abundance of
mesothelial cells exposed to high-venous pressure and
ascitis (Figure 2). Furthermore, the combination of both
pathological process may thus further contribute to
neurohumoral-axis activation facilitating CA-125 pro-
duction [36]. Additionally, the possible translocation of
bacteria or endotoxin formation during the exacerbation
of HF, a condition most likely to happen in subjects pre-
senting with right heart failure as well as gastrointestinal
functional impairment in the context of bowel congestion
with HF, may also play a key role in the “hyper-response”
of CA-125 from mesothelium [37].
On the other hand, the hypothetical link between peri-
cardial stimuli and elevation of CA-125 in subjects with
HF had also been observed. Seo et al. [38] ever reported
a 59% positive staining in the pericardial mesothelial cells,
while Soma et al. reported a negative finding [39]. More or
Figure 2 Illustrations regarding how HF may cause elevated hydrostatic pressure and congestion, leading to both serosal mechanical
stretch and third space fluid retention with resultant inflammation and cytokines release. These complex chain reactions were believed to
be the main cause of systemic CA-125 release.
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(pericardial, pleura or peritoneum) as a potential primary
source of CA-125 in HF or other non-malignant clinical
scenarios [40,41], while data regarding the severity or extent
of underlying stimuli, inducing media or modalities,
and whether such elevation in HF was also secondarily
influenced by effusions per se or other associated cytokines
still remained a debate [41]. Perhaps, all these possibilities
exist, but just contribute differentially according to the se-
verity and etiologies of HF. To clarify these issues, experi-
ments studying animal models of HF mimicking different
presentations of human HF encountered clinically may pro-
vide the solution. This approach will determine the major
production sites of CA-125 as well as the major stimuli in
various stages of HF.
Potential clinical application of CA-125 in HF
The range of value and potential clinical implication of
CA-125 regarding its predictive value in monitoring HF
beyond and the correlates with other well-established
HF markers (e.g. BNP or NT-ProBNP) remained largely
unknown. In general, serum CA-125 level seemed to be
7-fold higher (HF: 105.2 ± 139, range 4.6 to 1169.5 U/ml
vs Control: 14.9 ± 22 U/ml, respectively) in subjects with
acute HF, 2.5 times in chronic HF (HF: 68 ± 83, range 3
to 537 U/ml) [23] and nearly 1.5 times higher in female
HFpEF (HFpEF: 17.6 ± 10.2, range 4.94 to 104.3 U/ml)
[18], the value actually had wide range across a hetero-
geneous spectrum in specific subgroups of HF patients
[12,26,29,32,39]. Previous work on healthy volunteersshowed that serum CA-125 level differences may exist
between healthy pre- (mean level: 12.6 U/ml) and post-
menopausal women (10.5 U/ml) though without statistical
significance, with significant lower value was observed in
healthy men when compared to pre-menopausal women
(9.2 vs 12.6 U/ml, p = 0.007) [42]. Serum CA-125 had
shown significant correlation with BNP level, elevated
LV end-diastolic filling pressure and larger LA volume
in systolic HF [16], so far there is a paucity of data on
the incremental value of CA 125 when added on BNP.
Though comparable long-term (14 ± 2 months) predictive
value for CA 125 when compared to NT-ProBNP in stable,
chronic systolic HF had recently been tested in a feasibility
study with much lower cost (about 10 times less expensive
for CA 125 vs NT-ProBNP, roughly U.S. $1.07 vs $10.74)
[43]. The lack of change in serum CA 125 concentration
rather than NT-ProBNP seemed to confer higher risk of
death in systolic HF during a 3-month therapeutic interval.
[44] In addition to the potential clinical application in
patients with systolic heart failure, CA125 may help to
clarify the uncertain management of patients with HFpEF
[45]. The incremental value of CA 125 superimposed on
NT-ProBNP in female HFpEF was proved in our work
recently [18]. Interestingly, all these studies showed
statistically significant association between NT-ProBNP
and CA-125 level. However, all these reports were of
smaller sample size and used a diversity of clinical out-
comes as end-points. Thereafter, a large scale study
with specific HF patients population and well-defined
clinical outcomes may be necessary for a head-to-head
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used HF biomarkers.
Conclusion
With better understanding of the underlying biological
mechanisms and pathophysiological processes of heart
failure in the recent era, biomarker as a surrogate in dis-
ease screening, diagnosis, or as a guide to effects of ther-
apy or outcomes had broadened the utilization of these
tools by physicians in clinical settings. The incremental
clinical value by using multi-biomarker panel looking
into potentially diverse pathways or biological signaling
involved in a clinical disease entity are evolving. CA-125,
the glycoprotein primarily used for ovarian cancer screen-
ing or therapeutic monitoring, is gaining more and more
attention as another role in heart failure. Insights into the
understanding of its role and mechanisms involved in
heart failure had made it different from other biomarkers
for the same purpose, though questions and issues regard-
ing the real determinants for such glycoprotein release,
short- and long-term monitoring for treatment, and the
potential costs as a routine marker for heart failure may
worth further investigation.
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